Pharma Times

NOVEMBER 16, 2023

The funding will be used to develop new diagnostic tests, treatments and devices - News - PharmaTimes

Research 130

Research Development 130

BioTech 365

NOVEMBER 3, 2020

Press news Biocartis Group NV: Biocartis Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness Press news Biocartis Group NV: Biocartis Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness PRESS RELEASE: 3 … Continue reading →

Development 40

Development 40

BioTech 365

OCTOBER 19, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Breast cancer study uncovers new RNA targets for treatment and diagnostics.Breast cancer study uncovers new RNA targets for treatment and diagnostics arlene.weintraub Mon, 10/19/2020 – 08:41 from … Continue reading (..)

RNA 40

RNA Research 40

XTalks

JULY 13, 2023

Diagnostic test maker Quanterix has launched LucentAD, a biomarker-based prescription Alzheimer’s disease (AD) test to help in the diagnosis of the disease. The test is intended to help diagnose Alzheimer’s disease with other diagnostic tools. It is not intended as a standalone screening or diagnostic assay, according to Quanterix.

Protein 98

Protein FDA Approval Clinical Trials Clinical Trials 98

XTalks

APRIL 18, 2024

Consequently, there is a critical role for diagnostics to play in addressing this global health challenge,” said Matt Sause, CEO of Roche Diagnostics, in the company’s news release. “We Alongside its partnership with Roche on diagnostics, Lilly is also developing an amyloid beta therapy of its own, donanemab.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

Scienmag

SEPTEMBER 23, 2020

Credit: KAIST and IEEE Spectrum (Image usage restrictions: News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.)

Engineer 121

Engineer 121

Pharmaceutical Technology

SEPTEMBER 1, 2022

Analysts at GlobalData predict that the market for point-of-care (POC) diagnostic devices will reach $297.6bn by 2023, a growth of almost $1bn from 2015. As such, POC diagnostics are well positioned to challenge traditional centralised laboratory methods. Manufacturing challenges.

Manufacturing 130

Manufacturing Bacterium Reagent Production 130

STAT News

NOVEMBER 30, 2022

The decline in cancer death rates is clearly welcome news and coincides with a significant shift in cancer treatment through the development of new targeted therapies and accompanying diagnostic tests that guide their use. Read the rest…

Medicine 105

Medicine Development 105

XTalks

JUNE 6, 2023

Recently, Blue Earth Diagnostics announced that the US Food and Drug Administration (FDA) has granted approval to its novel, high-affinity radiohybrid prostate-specific membrane antigen (PSMA)-targeted PET imaging agent, Posluma (flotufolastat F 18). Gauden, CEO of Blue Earth Diagnostics, in the company’s news release.

FDA Approval 96

FDA Approval Clinical Trials Clinical Trials Marketing 96

World of DTC Marketing

AUGUST 9, 2021

86% of diagnostic device companies, 65% of pharma marketers, and over half of biotechs use social as a critical part of their marketing mix to reach HCPs. Most HCPs go to Medscape as a “first stop” in the morning to get their healthcare news. Doximity was flagged for having anti-vaccine information.

Nurses 294

Nurses Marketing Pharma Companies Production 294

Drug Discovery World

MAY 12, 2023

News round-up for 8-12 May by DDW Digital Content Editor Diana Spencer. Inspired by the relaunch of PerkinElmer’s Life Science and Diagnostics business this week as Revvity, my top five news story this week all relate to new drug discovery business developments.

Life Science 52

Life Science Drugs Licensing Licensing 52

XTalks

JANUARY 15, 2021

Ortho Clinical Diagnostics received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its VITROS SARS-CoV-2 antigen test for detection of active COVID-19 infection. The company says it can deliver five million tests a month and can increase to 15 million tests a month by February.

In-Vitro 105

In-Vitro Vaccination Vaccine Drugs 105

BioTech 365

MAY 4, 2021

NOTICE TO DISREGARD — CDx Diagnostics NOTICE TO DISREGARD — CDx Diagnostics SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) — We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark … Continue reading →

40

40

XTalks

JUNE 30, 2023

“The approval of Ultravist-300 and -370 in contrast-enhanced mammography gives physicians a new imaging option where conventional mammography might not be enough,” said Dr. Konstanze Diefenbach, head of Radiology Research and Development at Bayer, in the company’s news release. “We The FDA has not approved Iomeron.

FDA Approval 98

FDA Approval Radiology Trials Life Science 98

World of DTC Marketing

NOVEMBER 22, 2021

Your local CVS will be turned into “destinations that offer a range of healthcare services, from flu shots to diagnostic tests,” according to the company’s news release. They don’t want to weeks for lab tests and other diagnostic tests. This is exactly what patients want. Competitors are lining up.

Pharmacy 241

Pharmacy Nurses Doctors Doctor 241

BioTech 365

DECEMBER 14, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: PCR tests activated by light.A new approach by LMU chemists could help to significantly improve diagnostic tests based on PCR. The enzymes used are triggered by light … Continue reading →

Research 40

Research 40

XTalks

DECEMBER 1, 2021

With all the uncertainty around the new SARS-CoV-2 variant, Omicron (B.1.1.529), 1.1.529), diagnostic test makers are assuring people that their COVID-19 PCR tests work just fine in detecting the latest version of the coronavirus. Hence, there is no impact of the new variant on the PCR-based diagnostics.

Gene 105

Gene Genome Genomics Genetics 105

BioTech 365

DECEMBER 6, 2021

DGAP-News: XPhyto Therapeutics Corp. / XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH – The acquisition positions XPhyto to be a leading Biosensor producer … Continue reading → Key word(s): Acquisition 06.12.2021 / 09:05 The issuer is solely responsible for the content of this announcement.

40

40

BioTech 365

NOVEMBER 2, 2021

DGAP-News: SYNLAB AG / Key word(s): Mergers & Acquisitions 02.11.2021 / 07:30 The issuer is solely responsible for the content of this announcement. Significantly increased presence in Mexico: 100+ diagnostic service points and 1,700 employees A platform to further expand … Continue reading →

40

40

The Pharma Data

OCTOBER 21, 2020

21, 2020 — Women with invasive cervical cancer (ICC) have an increased rate of iatrogenic and noniatrogenic injuries during diagnostic workup, according to a study published online Oct. During the diagnostic workup of women with invasive cancer, there was also an increased rate of noniatrogenic injuries (IR, 0.65 Professional.

Research 52

Research 52

XTalks

APRIL 19, 2024

Among the greatest challenges in diagnostic imaging are delayed and missed findings. From day one, we have been committed to validating our AI tools on every type of CT scanner,” said Yasmina Chaibi, clinical affairs manager, Avicenna.AI, in a news release from the company announcing the FDA clearances. “In

Marketing 52

Marketing Radiology Development Manufacturing 52

XTalks

SEPTEMBER 28, 2020

LabCorp (NYSE:LH) may help lead the way with its backing of Resolution Bioscience’s new diagnostic blood test for lung cancer. Oncology is an area of intense focus for LabCorp, across our entire organization,” said Dr. Brian Caveney, president of LabCorp Diagnostics, in a press release. Personalized Approach.

Gene 105

Gene DNA Life Science Genotype 105

BioTech 365

JULY 20, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Faster diagnosis of deadly Hendra virus in horses.University of Queensland vets are diagnosing the deadly Hendra virus in horses faster than ever, developing a diagnostic point-of-care kit … Continue reading →

Development 40

Development Research 40

BioTech 365

MAY 11, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CRISPR tech could enable early diagnosis of devastating citrus disease.Penn State and U.S.

Scientist 40

Scientist Development Research 40

BioTech 365

MARCH 18, 2021

DGAP-News: XPhyto Therapeutics Corp. / XPhyto announces European Approval for 25 Minute COVID-19 PCR Test – CE Mark received for in vitro diagnostic … Continue reading → Key word(s): Miscellaneous 18.03.2021 / 09:05 The issuer is solely responsible for the content of this announcement.

In-Vitro 40

In-Vitro 40

XTalks

APRIL 6, 2022

If that happens, it is a big setback for patients and the doctors treating them,” said Dr. Rosenfeld in a news release by Cancer Research UK. In January, Inivata announced that it’s RaDaR assay met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC) and received the CE mark.

DNA 105

DNA In-Vitro Doctors Doctor 105

BioTech 365

JANUARY 20, 2021

DGAP-News: Secarna Pharmaceuticals GmbH & Co. Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved … Continue reading →

Bioinformatics 40

Bioinformatics 40

BioTech 365

OCTOBER 16, 2020

NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ SALT LAKE CITY, Oct. NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today … Continue reading → /NOT FOR DISTRIBUTION TO U.S. 16, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.

Genetics 40

Genetics Medicine 40

BioTech 365

OCTOBER 20, 2020

NEWS RELEASE – REGULATED INFORMATION 21 OCTOBER 2020, 07:00 A.M. CEST IRVINE, CA, and HERSTAL, BELGIUM – October 21, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the third quarter ended … Continue reading →

Regulation 40

Regulation 40

Drug Discovery World

JULY 8, 2022

A Covid-19 lawsuit, a heart attack treatment developed using spider venom and a collaboration to fight antimicrobial resistance (AMR) are some of the theme’s of this week’s news round-up. . News round-up by DDW’s Reece Armstrong for 4 – 8 July. CureVac lawsuit against BioNTech over Covid-19 vaccine technology.

Drugs 52

Drugs Clinical Trials Clinical Trials Vaccination 52

Drug Discovery World

APRIL 11, 2024

News that the UK is supporting two new initiatives to help further the development of antimicrobials alongside other solutions to tackle resistant infections is welcome news for a sector that has, in recent years, struggled to attract the funding and attention it deserves. There’s a long way to go until we reach these goals.

Bacteria 52

Bacteria Life Science Development Containment 52

The Pharma Data

OCTOBER 27, 2020

The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. “Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. Heinrich Jehle, managing director of 3a-Diagnostics.

RNA 52

RNA Drug Delivery Production In-Vitro 52

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Approval of the Month: Companion Diagnostic for Bayer’s Vitrakvi Should Lead to Improved Patient Outcomes. Co-Authors: Jenny Fielder. Ken Phelps.

Development 242

Development Bioequivalency Generic Drugs Production 242

XTalks

MAY 10, 2022

The University of Manchester research into the new HE4-based ovarian cancer test was funded by the health charity Wellbeing of Women and the study involved collaboration between researchers at the University of Manchester, University of Birmingham and University of Exeter.

Research 105

Research Development Clinical Trials Clinical Trials 105

The Pharma Data

DECEMBER 22, 2020

(NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. “We are truly excited and humbled to bring the power of diagnostic microarray testing to the Japanese market. Agilent Technologies Inc.

Genome 40

Genome Genomics Genetics In-Vitro 40

Drug Discovery World

DECEMBER 13, 2023

Investigators have leveraged its data to drive the development of new diagnostic and treatment approaches for HIV-associated malignancies. The ACSR’s mission is to acquire, store, and equitably distribute biospecimens, including tissue-based pathology data, and associated clinical data from PLWH to the scientific community-at-large.

Research 52

Research Development Drugs 52

The Pharma Data

DECEMBER 24, 2020

They found that average, inflation-adjusted out-of-pocket costs for diagnostic tests rose by as much as 190% over the study period. Their study, published online Dec. 23 in the journal Neurology, analyzed neurology care costs for more than 3.7 million people in a large private insurance claims database.

Research 52

Research 52